Clinical trials
Remission clinical trials
Below are recruiting remission clinical trials, each written for real people, not researchers. We’re tracking 136 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06034561RecruitingPhase 2
Bortezomib for relapsed or refractory acute lymphoblastic leukemia
This trial tests a chemotherapy combination that includes bortezomib for people whose acute lymphoblastic leukemia (ALL) has come back or not responded to previous treatments. It aims to offer a new option for those who haven't tried bortezomib before.
São Paulo, São PauloAges 16–60 - NCT06045819Recruiting
Predicting venetoclax response in newly diagnosed AML patients
This study looks at how blood levels of the drug venetoclax relate to remission in adults with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. It aims to help doctors dose the drug more effectively.
CaenAges 60–90 - NCT06050421Recruiting
RO DBT therapy for anorexia nervosa
This trial tests a therapy called Radically Open Dialectical Behaviour Therapy (RO DBT) for women with anorexia nervosa who have already reached a healthy weight. It focuses on helping people who tend to be overly self-controlled.
BarcelonaAges 18–65 - NCT06068179RecruitingPhase 2/Phase 3
Can a new combo help Graves' disease go into remission?
This trial tests a combination of two medicines (methimazole and mycophenolate) to see if they can help people with newly diagnosed Graves' disease go into remission faster and more safely. If you are newly diagnosed and haven't had treatment yet, this study might offer a way to get better control of your condition.
Xiamen, FujianAges 18–60 - NCT06091475Recruiting
Maintaining remission in improved dilated cardiomyopathy
This study tests whether people with dilated cardiomyopathy whose heart function has already recovered to normal can safely stop or reduce one of their heart medications while staying in remission. It aims to find the best way to keep the heart healthy without extra medicines.
LondonAges 18–85 - NCT06149910Recruiting
Study of Treatment Plans for Newly Diagnosed Multiple Myeloma
This study looks at whether a new treatment plan (called a clinical pathway) helps doctors make better decisions for people just diagnosed with multiple myeloma. It will review medical records and may ask you to use a secure online platform to share your health information.
Seattle, WashingtonAges 18 years+ - NCT06232694Recruiting
Combination therapy for newly diagnosed AML
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Nanjing, JiangsuAges 18–60 - NCT06238648RecruitingPhase 2
Epcoritamab for B-cell lymphoma after CAR-T therapy
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
Rochester, MinnesotaAges 18 years+ - NCT06318806Recruiting
OCD recovery study: therapy for full remission
This study tests a psychological treatment aimed at helping people with obsessive-compulsive disorder (OCD) reach full recovery. It is done remotely using your computer or phone, so you can participate from home.
Montreal, QuebecAges 18 years+ - NCT06596252RecruitingPhase 3
Budesonide Once vs Twice Daily for EoE Remission
This study tests whether a budesonide tablet that dissolves in the mouth works as well when taken once a day compared to twice a day for treating active eosinophilic esophagitis (EoE). It aims to help people with EoE achieve remission (feeling better and less inflammation).
Scottsdale, ArizonaAges 18–75 - NCT06368414RecruitingPhase 2
Stopping TKI in CML after asciminib
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
Incheon, IncheonAges 19 years+ - NCT06381219Recruiting
Heating milk or egg for kids with EoE
This study tests whether heating cow's milk or hen's egg (like baking them) can help children with EoE stay in remission. It's for children whose EoE is triggered by these foods and who are currently doing well (no active EoE).
Leuven, Vlaams-BrabantAges 1–18 - NCT06440135RecruitingPhase 1
Ziftomenib maintenance after stem cell transplant for AML
This trial tests if the drug ziftomenib can help prevent AML from coming back after a stem cell transplant. It is for people who have certain gene changes (KMT2A rearrangement or NPM1 mutation) and are in remission or near-remission before transplant.
Boston, MassachusettsAges 18 years+ - NCT06445803RecruitingPhase 1
CAR-T therapy for adults with certain blood cancers
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
Nanchang, JiangxiAges 18 years+ - NCT06463379RecruitingPhase 3
Intravenous pulse therapy for tough juvenile arthritis
This trial tests whether a type of intravenous medicine (called pulse therapy) can help children with arthritis that hasn't improved after other treatments. It aims to bring the disease into remission.
CairoAges 2–18 - NCT06555042Recruiting
Crohn's disease imaging study with PET-MRI
This study uses a special PET-MRI scan to look at inflammation and blood flow in the small intestine of people with Crohn's disease. It may help doctors better understand disease activity in the gut.
Turku, Southwest FinlandAges 18–70 - NCT06608732RecruitingPhase 2
CAR-T therapy plus stem cell transplant for B-cell ALL with MRD
This trial tests a combination of a CAR-T cell therapy (Inaticabtagene Autoleucel) followed by your own stem cells being transplanted back into you. It is for teenagers and adults who have B-cell acute lymphoblastic leukemia (ALL) that is in first complete remission but still has tiny amounts of cancer cells (called MRD) that can be detected by sensitive tests.
Tianjin, Tianjin MunicipalityAges 16–70 - NCT06653634RecruitingPhase 4
Optimizing treatment for kids with JIA in remission
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
BergenAges 2–17 - NCT06693310Recruiting
Stopping therapy safely in ulcerative colitis with no inflammation
This trial tests whether people with ulcerative colitis who have been in deep remission (no signs of active disease) can safely reduce or stop their current medication. It aims to find out if careful monitoring can keep them healthy without full-dose treatment.
Chicago, IllinoisAges 18–75 - NCT06694883Recruiting
Ulcerative colitis remission-recurrence study
This trial studies people with ulcerative colitis who are in a 'remission-recurrence' state, meaning their symptoms come and go. It aims to better understand this pattern and may help guide future treatments.
Dongcheng, Beijing MunicipalityAges Any age - NCT06699810RecruitingPhase 4
Understanding Diabetes Recovery After Severe Blood Sugar Crisis
This study looks at how certain people can recover from a dangerous blood-sugar emergency called DKA (diabetic ketoacidosis). Researchers want to understand why some patients improve and how to help them stay healthy long-term.
Atlanta, GeorgiaAges 18 years+ - NCT06714838RecruitingPhase 3
Rituximab for remission in chronic inflammatory demyelinating polyneuropathy
This trial tests a drug called rituximab to see if it can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) achieve remission. It may offer a new treatment option for those who are newly diagnosed or who are on maintenance therapy with wear-off symptoms or failed withdrawal attempts.
AmsterdamAges 18–80 - NCT06824168RecruitingPhase 2
Quizartinib maintenance for FLT3-ITD AML in remission
This trial tests two different doses of an oral targeted pill called quizartinib (a FLT3 inhibitor) to keep AML with a FLT3-ITD mutation in remission after initial chemo. If you are in first complete remission and haven't had a transplant, this might be an option to lower the chance of relapse.
Baltimore, MarylandAges 18 years+ - NCT06834646Recruiting
Comparing emergency care outcomes for cancer patients
This study looks at how cancer patients fare in different emergency departments over 30 days. It aims to find which settings lead to better outcomes for people with active cancer or who finished treatment less than a year ago.
ParisAges 18 years+
Hear when a new Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for remission?
- Yes. Clin2 currently lists 136 recruiting remission studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a remission trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a remission trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.